49 results
8-K
EX-99.2
RPTX
Repare Therapeutics Inc
7 May 24
Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results
4:10pm
ENA)N=44 RP2D: lunresertib 80mg BID + camonsertib 80mg QD 3d/4d Updated dosing strategy reduced Grade 3 anemia by ~halfHematologic safety profile … strategy
Lun + FOLFIRI combination promising Source: Clarivate-Decision Resources Group, No added heme tox observed to FOLFIRI alone MINOTAUR
8-K
1xd0d0v8srv3me157ddw
13 Oct 23
Repare Therapeutics Announces Positive Initial Data from Phase 1 MYTHIC Clinical Trial
9:47am
8-K
EX-99.1
gr2uo 2li7gb0zjk
13 Oct 23
Repare Therapeutics Announces Positive Initial Data from Phase 1 MYTHIC Clinical Trial
9:47am
8-K
EX-99.1
l8syiwykd
28 Apr 23
Repare Therapeutics Appoints Susan Molineaux, Ph.D., to Its Board of Directors
4:27pm
8-K
EX-99.1
29ojeldktspa7c6p
18 Apr 23
Repare Therapeutics Presents Initial Clinical Data from the Phase 1/2 TRESR and ATTACC
10:24am
424B5
j6plvlj2yc
4 Aug 22
Prospectus supplement for primary offering
5:00pm
8-K
EX-99.1
i2w736
4 Aug 22
Repare Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results
4:14pm
8-K
EX-99.1
tmt2b q90pltna63r
1 Jun 22
Entry into a Material Definitive Agreement
4:01pm